Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study
| Autor: | Ronald A. Fleming, Robert L. Capizzi, Gary L. Rosner, Raymond B. Weiss, George A. Omura, Bruce A. Peterson, Robert J. Mayer, Clara D. Bloomfield, Lawrence K. Oliver, David A. Van Echo, Stephen J. Smith, Richard L. Schilsky, Richard T. Silver, Charles A. Schiffer |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Adolescent Daunorubicin medicine.medical_treatment Toxicology Gastroenterology Pharmacokinetics White blood cell Internal medicine medicine Humans heterocyclic compounds Pharmacology (medical) Aged Pharmacology Chemotherapy business.industry Cytarabine food and beverages Myeloid leukemia biochemical phenomena metabolism and nutrition Middle Aged medicine.disease carbohydrates (lipids) Leukemia medicine.anatomical_structure Treatment Outcome Oncology Leukemia Myeloid Toxicity Immunology Acute Disease lipids (amino acids peptides and proteins) Female business medicine.drug |
| Zdroj: | Cancer chemotherapy and pharmacology. 36(5) |
| ISSN: | 0344-5704 |
| Popis: | The pharmacokinetics of cytarabine (ara-C) were determined in 265 patients with acute myeloid leukemia (AML) receiving ara-C (200 mg/m2 per day for 7 days as a continuous infusion) and daunorubicin during induction therapy. The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) microM and 134 (71) l/h per m2 respectively. Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2, P = 0.025) than females. Significant correlations were noted between ara-C Cl and the pretreatment, peripheral white blood cell count (P = 0.005) and pretreatment blast count (P = 0.020). No significant differences in ara-C Css or Cl were noted in patients achieving complete remission compared with those failing therapy (P = 0.315, P = 0.344, respectively). No significant correlations were observed between ara-C pharmacokinetic parameters and several indices of patient toxicity. Our findings indicate that variability in ara-C disposition in plasma at this dosage level does not correlate with remission status or toxicity in patients with AML receiving initial induction therapy with ara-C and daunorubicin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink